Viridian Therapeutics, Inc. (FRA:1S1)

Viridian Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 4, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	2,627	1,467	1,036	1,100	378	53
Market Cap Growth	73.50%	41.55%	-5.81%	191.32%	618.50%	286.62%
Enterprise Value	2,388	944	895	835	333	36
Last Close Price	27.45	18.20	19.90	26.60	17.30	13.06
PS Ratio	43.54	5028.17	3647.53	663.46	144.94	61.23
PB Ratio	6.13	2.26	2.59	2.98	2.29	0.54
P/TBV Ratio	9.81	3.15	4.86	4.65	7.97	-
EV/Sales Ratio	39.25	3236.51	3150.76	503.65	127.79	41.48
Debt / Equity Ratio	0.05	0.03	0.05	0.01	0.00	0.00
Asset Turnover	0.11	0	0.00	0.01	0.02	0.01
Quick Ratio	11.06	14.99	17.93	12.73	14.48	11.96
Current Ratio	11.28	15.43	18.27	12.93	14.68	12.14
Return on Equity (ROE)	-49.89%	-48.48%	-56.80%	-44.57%	-51.61%	-163.07%
Return on Assets (ROA)	-30.08%	-30.32%	-34.37%	-26.28%	-29.75%	-31.36%
Return on Capital (ROIC)	-32.26%	-32.26%	-36.80%	-28.52%	-32.28%	-35.04%
Return on Capital Employed (ROCE)	-61.70%	-43.10%	-54.90%	-33.40%	-41.90%	-33.60%
Earnings Yield	-7.96%	-17.78%	-20.76%	-11.05%	-18.49%	-172.21%
FCF Yield	-10.59%	-15.33%	-16.16%	-8.05%	-12.79%	-46.39%
Buyback Yield / Dilution	-34.66%	-51.68%	-39.48%	-169.22%	-235.07%	-70.27%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.